@article{oai:nagoya.repo.nii.ac.jp:00015382,
 author = {WATANABE, YUZO and ASAI, KANlCHI and OKURA, TAKANOBU and KAWAHARA, HlROHlSA and SAKAMOTO, NOBUO},
 issue = {3-4},
 journal = {Nagoya Journal of Medical Science},
 month = {Mar},
 note = {The clinical effect of 1α-OH-D3, a synthetic analogue of the active form of Vitamin D, was investigated in hemodialized patients. The administration of 1α-OH-D3 with supplementary calcium therapy (at doses equivalent to 520 mg of elemental calcium per day) produced a significant biochemical improvement characterized by an increase in serum calcium concentration, lowered serum inorganic phosphate content and diminution of(Ca)X(Pi), without any appreciable increase in parathyroid hormone (PTH). There was actually no patient showing exacerbation in skeletal X-ray findings following the treatment. The reversal from a lowered serum calcium level might be largely ascribable to the improvement of the alimentary balance of calcium. Also, the decrease in serum inorganic phosphate value might have been brought about by the suppression of phosphorus absorption by supplementary calcium lactate administraion, by phosphorus deposition in bones, and by suppression of bone resorption by PTH. It was found that a calcium concentration of 3.5 mEq / L approx, in the dialysate was adequate for periodic hemodialysis. The data indicated the effectiveness of the administration of 1α-OH-D3 with calcium supplementation for the prevention and treatment of renal osteodystrophy in the maintenance of hemodialized patients.},
 pages = {89--101},
 title = {The Clinical Investigation of 1α-OH-D3 on Hemodialized Patients},
 volume = {44},
 year = {1982}
}